| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
We develop new technologies that allow neural cell type-specific and neural pathway-specific gene transduction with viral vector alone by modification of AAV capsid proteins. The strategy is simple, and we pursued research based on the following two policies. (i) Removal of nonspecific infectivity: it was confirmed by cultured cells that infectivity was dramatically decreased by replacing various amino acid sequences prescribing extensive infection directivity. Subsequently, verification is underway with primary cultured neurons and adult mice. (ii) Granting new infectivity: we aim to acquire new infectivity by adding / inserting specific sequence to capsid protein. Candidate specific sequences were prepared and purified. We are proceeding with verification in adult mouse.
|
